Webinar: The clinical value of cystatin C, by Dr. E. Sundrehagen, CSO

08. Sep 2020 | 3 min read

Webinar: The clinical value of cystatin C, by Dr. E. Sundrehagen, CSO

Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function, as a reduction in the GFR causes a rise in the concentration of cystatin C. In this webinar Dr. Erling Sundrehagen, the co-founder of Gentian and the company’s CSO, will elaborate on the following topics:

  • Determining Glomerular Filtration Rate (GFR)
  • The history of cystatin C
  • Properties of cystatin C and its clinical value
  • Interference and avian antibodies
  • The benefits of the Gentian Cystatin C immunoassay
  • Cystatin C in addition to creatinine

Watch the webinar here

 

 

 

The Gentian Cystatin C Immunoassay

The Gentian Cystatin C Immunoassay was Gentian’s first product and was launched in 2006, filling the significant gap in the IVD market for a high quality, sensitive, turbidimetric cystatin C immunoassay.

  • ERM-DA471/IFCC standardised
  • FDA510 (k) cleared and CE-marked
  • Available for a wide range of clinical analysers with documented high inter instrument accuracy1
  • One of the methods used to evaluate the commutability of the World standard produced by IFCC2
  • Particle-Enhanced Turbidimetric Immunoassay (PETIA)

Contact us

Please send an email to marketing@gentian.com or fill out the form below to get in touch with Product Manager for cystatin C

References

  1. Eckfeldt JH et al. Arch Pathol Lab Med 2015;139:888-93
  2. Grubb A et al. Clin Chem Lab Med 2010;48: 16-19

 

 

You may also read


Meet Gentian and explore circulating calprotectin at Autoimmunity 2026

May 05, 2026

Meet Gentian and explore circulating calprotectin at Autoimmunity 2026

Discover new insights in inflammation with calprotectin We are excited to announce that Gentian will be..

GCAL® Calprotectin - From insights to impact - April 2026

Apr 21, 2026

GCAL® Calprotectin - From insights to impact - April 2026

Continuing the GCAL® journey: calprotectin's power to assess inflammation The first quarter has brought..